Martingale Asset Management L P Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Martingale Asset Management L P grew its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 65.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,740 shares of the specialty pharmaceutical company’s stock after purchasing an additional 13,719 shares during the period. Martingale Asset Management L P owned about 0.17% of ANI Pharmaceuticals worth $2,073,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Innealta Capital LLC acquired a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $65,000. Ridgewood Investments LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at $85,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the period. XTX Topco Ltd acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth $207,000. Finally, Profund Advisors LLC purchased a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $225,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Activity

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 33,981 shares of company stock valued at $1,970,066 in the last ninety days. 12.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Raymond James lifted their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. StockNews.com lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $57.23 on Friday. The firm has a fifty day moving average price of $58.22 and a 200 day moving average price of $60.67. The stock has a market cap of $1.20 billion, a PE ratio of -104.05 and a beta of 0.71. ANI Pharmaceuticals, Inc. has a 1-year low of $48.20 and a 1-year high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same period in the prior year, the firm earned $1.05 EPS. The business’s revenue was up 12.5% on a year-over-year basis. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.